Spevigo
(Spesolimab)ApprovedMonoclonal antibody
Boehringer IngelheimSpesolimab is used to treat flare-ups of generalized pustular psoriasis, a severe skin condition where painful pus-filled bumps cover large areas of the body.[2] Spevigo is currently approved and in use across 13 indications[4].[1]
Spevigo is one of 248 monoclonal antibody programs targeting Pyoderma Gangrenosum. It is currently in Approved.
13
Indications
28
Total Trials
3
Active Trials
247
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
605 competitors in Psoriasis
#DrugCompanyPhaseTrials
1Spevigo
Boehringer IngelheimApproved
Cosentyx
NovartisPreclinical
Stelara
Johnson & JohnsonPreclinical
Taltz
Eli LillyPreclinical
Bimzelx
UCBPreclinical
Humira
CCelltrion
Preclinical
Ilumya
Sun Pharmaceutical Industries, Inc.Preclinical
Raptiva
RochePreclinical
Remicade
OOrganon and Co
Preclinical
Siliq
BBausch Health Americas, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Generalized Pustular Psoriasis7 trials
Show 4 more trials
Ulcerative Colitis4 trials
Hidradenitis Suppurativa4 trials
Palmoplantar Pustulosis3 trials
Crohn's Disease3 trials
6 more indications
Netherton syndrome1 trial
Atopic Eczema1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Spevigo drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Spesolimab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- IL-36R Inhibitor[3]
- Modality
- Monoclonal antibody[3]
- Highest Phase
- Approved[1]
- Company